SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-026338
Filing Date
2024-02-22
Accepted
2024-02-22 08:00:39
Documents
14
Period of Report
2024-02-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm246898d1_8k.htm   iXBRL 8-K 30187
  Complete submission text file 0001104659-24-026338.txt   204934

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rigl-20240222.xsd EX-101.SCH 3006
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE rigl-20240222_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rigl-20240222_pre.xml EX-101.PRE 22353
15 EXTRACTED XBRL INSTANCE DOCUMENT tm246898d1_8k_htm.xml XML 3630
Mailing Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-624-1100
RIGEL PHARMACEUTICALS INC (Filer) CIK: 0001034842 (see all company filings)

IRS No.: 943248524 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-29889 | Film No.: 24662363
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)